As a leader in the field of histopathology, counting on an experienced team of pathologists, CellCarta has been involved in many clinical studies and developed several assays.
Services from both histopathology and genomic platforms can be coordinated to provide integrated solutions and our scientific team can customize assays based on your specific needs.
With proficiency in multiple staining platforms, the histopathology team can support large scale studies from discovery to late phase clinical trials and maintain a quick turnaround time aligned with clinical needs. Well established sample processing protocols, including the possibility of sample rescue for poor formalin-fixed, paraffin-embedded (FFPE) samples, ensures quality data.
Through the addition of Mosaic Laboratories, pioneers in multiplex IHC services, CellCarta now offers a wider histopathology testing menu. Find out more about Mosaic Laboratories – A CellCarta Company.
Leveraging our strong expertise in immunohistochemistry (IHC) and immunofluorescence (IF) assays, get a detailed picture of the abundance, distribution, and localization of antigens of interests in tissues or cells. IHC assays can be performed with both chromogenic and fluorescent labeling methods and all major platforms are available including the ones from Ventana Medical Systems, Dako, and Leica Biosystems BOND.
Highly multiplex immunofluorescence imaging can bring valuable and extensive data from scarce clinical samples. Using multiplex or single assays, our team can look at various CD markers, T-cell activation and exhaustion markers, antigen presentation and immune cell infiltration markers, and characterize the tumor microenvironment (TME).
This molecular analysis method, which provides the precise localization and quantification of nucleic acids such as DNA, mRNA, and microRNA, is a powerful tool in oncology for the analysis of genetic abnormalities. CellCarta offers all methods of probe detection: fluorescence (FISH), chromogenic (CISH), and silver (SISH) in situ hybridization.
Using single ISH, our team can screen for the expression of a specific gene. We also harnessed to power of dual ISH, an important tool to assess gene inversion, translocation, or duplication in cancer sample analysis.
This simple yet essential technique provides a broad view of various cellular features. Our pathologists commonly use it to investigate the presence of tumor infiltrating lymphocytes (TILs) and stromal TILs in clinical samples.
Our Hematoxylin and Eosin (H&E) staining services provide a reliable view of cellular and tissue structures in formalin-fixed, paraffin-embedded, or fresh frozen tissue. For consistent results, all our H&E staining procedures are monitored by our certified pathologists.
A high-quality, experienced team of pathologists skilled in working on projects with pharmaceutical companies is central to CellCarta operations and assay development. The group is comprised of more than 20 in-house anatomic and molecular pathologists working in our US, Belgium and China labs. A team of skilled imaging scientists trained in digital pathology, imaging, and algorithm development work in collaboration with them to deliver optimal data.
Both teams have access to the latest imaging technologies from 3DHistech, Akoya, BioView, Leica Biosystems (Aperio®), Roche/Ventana, and Zeiss as well as key image analysis software: imageDxTM, Visiopharm®, HALO®, and inForm®.
In addition to ensuring our certified pathologists and imaging scientists have access to the best tools and training programs, we use Pathomation’s Global Connectivity platform to integrate digital image viewing into our LIMS, pathology training platform and Customer Portal, facilitating both internal as well as external collaboration and providing lean and hyper-efficient digital pathology workflows.
To support the teamwork and continuing education that is essential for pathology activities, we have developed the digital pathology scoring and annotation platform, Pathotrainer for both internal and client programs. to our clients called:
Circulating tumor cells (CTCs) provide a dynamic view of cancer progression and can be detected in peripheral blood. Our well-defined blood processing workflow in combination with the RareCyte® platform (CyteFinder®) allow us to easily identify and phenotype these cells.
Using this technology, we offer the possibility to perform fluorescent staining on single cells. The reproducible automated staining and analysing process enables the use of this platform in large scale clinical trials.